Virbac SA Asset Resilience Ratio

Latest as of December 2024: 0.23%

Virbac SA asset resilience ratio. Virbac SA (VIRP) has an Asset Resilience Ratio of 0.23% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VIRP defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€4.31 Million
≈ $5.04 Million USD Cash + Short-term Investments

Total Assets

€1.90 Billion
≈ $2.22 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Virbac SA (2011–2024)

Asset resilience ratio of Virbac SA from 2011 to 2024. This chart shows how Virbac SA's Asset Resilience Ratio has changed over time. Read Virbac SA (VIRP) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Virbac SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VIRP current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €4.31 Million 0.23%
Total Liquid Assets €4.31 Million 0.23%

Asset Resilience Insights

  • Limited Liquidity: Virbac SA maintains only 0.23% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Virbac SA Industry Peers by Asset Resilience Ratio

Compare Virbac SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Novartis AG
SW:NOVN
Drug Manufacturers - General 0.08%
AstraZeneca PLC
NASDAQ:AZN
Drug Manufacturers - General 0.10%
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 5.33%
Novartis AG
MX:NVSN
Drug Manufacturers - General 0.08%
Biogen Inc
NASDAQ:BIIB
Drug Manufacturers - General 0.00%
Organon & Co
NYSE:OGN
Drug Manufacturers - General 4.46%
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
Drug Manufacturers - General 0.53%
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
Drug Manufacturers - General 1.97%

Virbac SA Asset Resilience Ratio by Year (2011–2024)

Virbac SA asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Virbac SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.23% €4.31 Million
≈ $5.04 Million
€1.85 Billion
≈ $2.16 Billion
+0.06pp
2023-12-31 0.17% €2.50 Million
≈ $2.92 Million
€1.46 Billion
≈ $1.70 Billion
-0.01pp
2022-12-31 0.18% €2.49 Million
≈ $2.91 Million
€1.36 Billion
≈ $1.59 Billion
+0.04pp
2021-12-31 0.15% €1.78 Million
≈ $2.08 Million
€1.22 Billion
≈ $1.43 Billion
-0.52pp
2020-12-31 0.67% €7.39 Million
≈ $8.64 Million
€1.11 Billion
≈ $1.30 Billion
+0.64pp
2019-12-31 0.03% €342.00K
≈ $399.83K
€1.32 Billion
≈ $1.55 Billion
-0.03pp
2018-12-31 0.06% €739.00K
≈ $863.97K
€1.27 Billion
≈ $1.49 Billion
-0.05pp
2017-12-31 0.11% €1.34 Million
≈ $1.57 Million
€1.28 Billion
≈ $1.49 Billion
+0.02pp
2013-12-31 0.08% €735.00K
≈ $859.29K
€896.23 Million
≈ $1.05 Billion
-0.11pp
2011-12-31 0.19% €1.14 Million
≈ $1.34 Million
€588.63 Million
≈ $688.18 Million
--
pp = percentage points

About Virbac SA

PA:VIRP France Drug Manufacturers - General
Market Cap
$3.52 Billion
€3.01 Billion EUR
Market Cap Rank
#4741 Global
#83 in France
Share Price
€359.50
Change (1 day)
+0.00%
52-Week Range
€302.00 - €384.00
All Time High
€437.64
About

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more